opioid, FDA

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Plus, NBC News spoke to trans service members about their thoughts on President Trump's executive order banning trans people from enlisting and serving in the military.